DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Prohance (Gadoteridol) - Skin Hypertrophy - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Skin Hypertrophy (46)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Prohance (Gadoteridol) where reactions include skin hypertrophy. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 46   Next >>

Possible Prohance side effects in 49 year old male

Reported by a lawyer from United States on 2012-08-02

Patient: 49 year old male, weighing 77.1 kg (169.6 pounds)

Reactions: Pain, Joint Contracture, Erythema, Muscle Tightness, Joint Stiffness, Myosclerosis, Rash Pruritic, Joint Range of Motion Decreased, Skin Lesion, Oedema Peripheral, Musculoskeletal Stiffness, Oedema, Depression, Extremity Contracture, General Physical Health Deterioration, Muscular Weakness, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Skin Induration, Skin Tightness, Skin Plaque, Joint Swelling, Quadriparesis, Mobility Decreased

Drug(s) suspected as cause:
Omniscan

Multihance
    Indication: Product Used FOR Unknown Indication

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-05-19
    End date: 2006-05-19

Magnevist
    Dosage: 15 ml, unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2006-10-13
    End date: 2006-10-13

Omniscan
    Dosage: 50 ml omniscan+co2
    Indication: Fistulogram
    Start date: 2006-08-04
    End date: 2006-08-04

Gadolinium IN Unspecified Drug
    Start date: 2004-05-19
    End date: 2004-05-19

Omniscan
    Dosage: 20 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-08-05
    End date: 2006-08-05

Prohance
    Indication: Computerised Tomogram Head
    Start date: 2004-05-19
    End date: 2004-05-19

Optimark
    Indication: Product Used FOR Unknown Indication

Magnevist
    Dosage: 20 ml, unk
    Start date: 2006-10-17
    End date: 2006-10-17

Other drugs received by patient: Coumadin; Renagel; Aranesp; Lyrica; Norvasc; Lamisil; Percocet; Gentamicin; Procardia XL; Ferrous Sulfate TAB; Sodium Bicarbonate; Acetaminophen; Venofer; Coreg; Actos; Prinivil; Synthroid; Amitriptline Hydrochloride TAB; Nateglinide; Pentoxifylline; Phoslo; Procrit; Epogen; Nexium; Elavil; Lipitor; Lantus; Trental; Benadryl; Avelox; Pletal; Tambocor; Atenolol; Zyvox; Lopid; Nephrocaps; Bactrim DS; Restoril; Clonidine; Starlix; Accupril; Vancomycin; Lasix; Potassium Chloride; Glucotrol; Renagel; Nicotine



Possible Prohance side effects in female

Reported by a consumer/non-health professional from United States on 2012-08-01

Patient: female

Reactions: Pruritus, Pain, Joint Contracture, Myosclerosis, Skin Ulcer, Injury, Fibrosis, General Physical Health Deterioration, Skin Hypertrophy, Skin Induration, Nephrogenic Systemic Fibrosis, DRY Skin, Deformity, Skin Plaque, Skin Tightness, Emotional Distress, Anxiety, Arthralgia, Tendon Disorder, Disability

Drug(s) suspected as cause:
Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Prohance
    Indication: Angiogram

Magnevist
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Indication: Angiogram

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Angiogram

Multihance
    Indication: Angiogram

Omniscan
    Indication: Angiogram

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Nuclear Magnetic Resonance Imaging



Possible Prohance side effects in 79 year old female

Reported by a physician from United States on 2012-07-20

Patient: 79 year old female, weighing 63.6 kg (140.0 pounds)

Reactions: Skin Wrinkling, Pruritus, Pain, Muscle Rigidity, Erythema, Joint Stiffness, Fatigue, Joint Range of Motion Decreased, Musculoskeletal Stiffness, Oedema, Injury, Extremity Contracture, Skin Hypertrophy, DRY Skin, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Tightness, Emotional Distress, Anxiety, Arthralgia

Adverse event resulted in: death

Drug(s) suspected as cause:
Omniscan
    Dosage: dose reported as eight 20ml vials (160ml)
    Start date: 2005-09-20
    End date: 2005-09-20

Multihance
    Indication: Nuclear Magnetic Resonance Imaging Abdominal

Prohance
    Indication: Nuclear Magnetic Resonance Imaging Abdominal

Multihance
    Indication: Angiogram

Gadolinium Zeolite
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2001-04-25
    End date: 2001-04-25

Gadolinium Zeolite
    Start date: 2005-08-16
    End date: 2005-08-16

Omniscan
    Dosage: route reported as ^first via distal port and then via the proximal port^
    Indication: Angiogram
    Start date: 2003-12-04
    End date: 2003-12-04

Optimark
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2005-08-16
    End date: 2005-08-16

Optimark
    Indication: Angiogram

Gadolinium Zeolite
    Start date: 2001-05-03
    End date: 2001-05-03

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2001-04-25
    End date: 2001-04-25

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium Zeolite
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2001-03-05
    End date: 2001-03-05

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2003-05-23
    End date: 2003-05-23

Prohance
    Indication: Angiogram

Magnevist
    Indication: Angiogram
    Start date: 2001-05-03
    End date: 2001-05-03

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging Brain

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: dose reported as ^11^ 20ml vials
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-09-01
    End date: 2005-09-01

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Epogen; Imdur; Folic Acid; Potassium Chloride; Lovastatin; Diltiazem; Furosemide; Nephrovite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Renagel; Potassium Chloride; Amiodarone HCL; Hydralazine HCL; Aspirin; Niferex; Coreg; Plendil; Venofer; Zemplar



Possible Prohance side effects in 51 year old female

Reported by a lawyer from United States on 2012-07-09

Patient: 51 year old female, weighing 64.1 kg (141.0 pounds)

Reactions: Peripheral Coldness, Pruritus, Skin Exfoliation, Pain, Erythema, Skin Fissures, Joint Stiffness, Skin Discolouration, Dermatitis, Joint Range of Motion Decreased, Oedema Peripheral, Skin Haemorrhage, Fibrosis, Injury, Pain in Extremity, Motor Dysfunction, DRY Skin, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Skin Induration, Sclerodactylia, Skin Tightness, Emotional Distress, Anxiety, Burning Sensation, Dysstasia, Activities of Daily Living Impaired, Insomnia, Mobility Decreased, Scar

Drug(s) suspected as cause:
Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Fistulogram

Magnevist
    Dosage: unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2001-01-11
    End date: 2001-01-11

Optimark
    Indication: Venogram

Multihance
    Indication: Venogram

Magnevist
    Indication: Arteriovenous Fistula Operation
    Start date: 2006-11-28
    End date: 2006-11-28

Prohance
    Indication: Venogram

Prohance
    Indication: Fistulogram

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: unk, once
    Indication: Venous Pressure Increased
    Start date: 2004-12-09
    End date: 2004-12-09

Magnevist
    Indication: Dialysis Efficacy Test
    Start date: 2006-09-26
    End date: 2006-09-26

Magnevist
    Indication: Dialysis Device Insertion

Omniscan
    Indication: Fistulogram

Optimark
    Indication: Fistulogram

Omniscan
    Indication: Venogram

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Levothroid; Atenolol; Phoslo; Epoetin NOS; PEG-3350 and Electrolytes; Levothroid; Calcium Carbonate; Renagel; Epogen; Procardia XL; Pravachol; Sensipar; Vitamin B12; Imodium; Cardizem; Prednisone; Amiodarone HCL; Allopurinol; Immune Globulin NOS; Benadryl; Omeprazole; Protonix; Renagel; Plendil; Immune Globulin NOS; Acetaminophen; Pravastatin; Atenolol; Coumadin; Reglan; Vicodin; Nephro-Vite [vitamins Nos]; Immune Globulin NOS; Immune Globulin NOS; Acetaminophen; Nitroglycerin; Tramadol HCL; Coumadin; Calcium Carbonate; Sensipar; Cyclosporine; Acetaminophen; Benadryl; Benadryl; Calcitriol; Fosrenol; Metoclopramide; Metoprolol Tartrate; Nifedipine; Acetaminophen; Benadryl; Ureacin; Loperamide; Corticosteroids; Coumadin; Protonix; Allopurinol; Prilosec; Immune Globulin NOS; Acetaminophen; Acetaminophen; Benadryl



Possible Prohance side effects in male

Reported by a consumer/non-health professional from United States on 2012-06-28

Patient: male, weighing 83.0 kg (182.6 pounds)

Reactions: Pruritus, Pain, Quality of Life Decreased, Muscular Weakness, Orthostatic Hypotension, DRY Skin, Stasis Dermatitis, Nephrogenic Systemic Fibrosis, Rash, Skin Hypertrophy, Skin Tightness, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Mobility Decreased

Drug(s) suspected as cause:
Optimark
    Indication: Angiogram

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist

Prohance
    Indication: Angiogram

Magnevist
    Indication: Angiogram

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging Brain

Multihance
    Indication: Angiogram

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Angiogram

Magnevist
    Dosage: 20 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 1998-05-18
    End date: 1998-05-18

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Pepcid; Meclizine; Prednisone TAB; Diovan; Plavix; Nexium; Flomax; Warfarin Sodium; Covera-HS; Norvasc; Nephrocaps [vit C,vit H,b12,b9,b3,pantothen Ac,b6,b2,b1 Hcl]; Coumadin; Epogen; Monopril; Cytoxan; Accupril; Aspirin; Sensipar; Novolin [insulin]; Hydralazine Hydrochloride; Ancef; Acetaminophen; Kayexalate; Humulin [insulin Human Injection, Isophane]; Norvasc; Phoslo; Catapres; Prevacid; Renvela; Lasix; Amiodarone Hydrochloride; Ascorbic Acid; Fish OIL; Sodium Polystyrene Sulfonate; Procrit; Zaroxolyn; Diuril; Darvocet; Neurontin; Renagel; Clonidine; Levothyroxine; Demadex; Potassium Chloride; Verapamil; Percocet; Lopressor; Lipitor



Possible Prohance side effects in 58 year old female

Reported by a consumer/non-health professional from United States on 2012-06-22

Patient: 58 year old female, weighing 70.0 kg (154.0 pounds)

Reactions: Pruritus, Scab, Skin Burning Sensation, Skin Hyperpigmentation, Joint Stiffness, Anhedonia, Oedema Peripheral, Skin Swelling, Peau D'orange, Pain in Extremity, Muscular Weakness, Skin Disorder, Skin Induration, Livedo Reticularis, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Rash Macular, Anxiety, Mobility Decreased, Scar, Skin Fibrosis

Drug(s) suspected as cause:
Magnevist
    Dosage: 20 ml, unk
    Indication: Imaging Procedure
    Start date: 2003-12-20

Optimark
    Indication: Imaging Procedure

Multihance
    Indication: Imaging Procedure

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2005-05-26
    End date: 2005-05-26

Prohance
    Indication: Imaging Procedure

Magnevist
    Dosage: 15 ml, unk
    Indication: Angiogram
    Start date: 2006-05-30

Omniscan
    Indication: Imaging Procedure

Other drugs received by patient: Klonopin; Calcitriol; Norvasc; Zemplar; Epogen; Folbee; Immunosuppressive Agents; Sensipar; Plavix; Colchicine; Renagel; Robaxin; Synthroid; Levothyroxine Sodium; Phoslo; Immunosuppressive Agents; Corticosteroids; Hormones and Related Agents; Coumadin; Gabapentin; Antithrombotic Agents; Steroid Antibacterials; Midodrine Hydrochloride; Aspirin; Neurontin; Iron Supplement; Nephrocaps



Possible Prohance side effects in 54 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-01

Patient: 54 year old male, weighing 93.9 kg (206.5 pounds)

Reactions: Hyperkeratosis, Skin Exfoliation, Pain, Skin Hyperpigmentation, Scleroderma, Erythema, Joint Range of Motion Decreased, Oedema Peripheral, Skin Swelling, Rash Papular, General Physical Health Deterioration, Skin Induration, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, DRY Skin, Deformity, Skin Plaque, Sclerodactylia, Skin Tightness, Macule, Mobility Decreased

Drug(s) suspected as cause:
Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 1999-10-13
    End date: 1999-10-13

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2007-03-21
    End date: 2007-03-21

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-11-18
    End date: 2008-11-18

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 1999-10-28
    End date: 1999-10-28

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2006-01-14
    End date: 2006-01-14

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 1999-09-20
    End date: 1999-09-20

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Fistulogram
    Start date: 1999-10-08
    End date: 1999-10-08

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2006-02-04
    End date: 2006-02-04

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-03-19
    End date: 2008-03-19

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 1999-09-27
    End date: 1999-09-27

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-08-13
    End date: 2008-08-13

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Sensipar; Renal [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Aspirin; Hydrocodone Bitartrate + Acetaminophen; Phoslo; Calcium Acetate; Rena-Vite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Iron; Renvela



Possible Prohance side effects in 57 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-31

Patient: 57 year old male, weighing 77.1 kg (169.6 pounds)

Reactions: Skin Wrinkling, Pruritus, Pain, Erythema, Joint Stiffness, Fatigue, Anhedonia, Joint Range of Motion Decreased, Skin Lesion, Oedema Peripheral, Musculoskeletal Stiffness, Injury, Extremity Contracture, Peau D'orange, Pain in Extremity, Excoriation, Muscular Weakness, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Hypoaesthesia, Skin Hypopigmentation, DRY Skin, Skin Plaque, Skin Tightness, Emotional Distress, Anxiety, Arthralgia, Scar, Skin Fibrosis, Mobility Decreased

Drug(s) suspected as cause:
Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: unk unk, once
    Indication: Nuclear Magnetic Resonance Imaging Renal
    Start date: 2005-08-25
    End date: 2005-08-25

Omniscan
    Dosage: unk, once
    Indication: Angiogram Peripheral
    Start date: 2005-08-30
    End date: 2005-08-30

Omniscan
    Dosage: unk, once
    Start date: 2005-09-28
    End date: 2005-09-29

Omniscan
    Dosage: unk, once
    Start date: 2005-11-03
    End date: 2005-11-03

Omniscan
    Dosage: unk, once
    Start date: 2005-10-03
    End date: 2005-10-03

Optimark
    Dosage: 19 ml, unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2005-04-20
    End date: 2005-04-20

Omniscan
    Dosage: unk

Omniscan
    Dosage: unk, once
    Start date: 2005-10-01
    End date: 2005-10-01

Omniscan
    Dosage: unk, once
    Start date: 2005-10-18
    End date: 2005-10-18

Gadolinium IN Unspecified Drug
    Dosage: unk unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-03-17
    End date: 2006-03-17

Omniscan
    Dosage: unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-09-08
    End date: 2005-09-08

Omniscan
    Dosage: unk, once
    Start date: 2005-09-06
    End date: 2005-09-06

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: unk, once
    Indication: Venogram Renal
    Start date: 2005-09-01
    End date: 2005-09-01

Omniscan
    Dosage: unk, once
    Start date: 2005-10-21
    End date: 2005-10-21

Optimark
    Dosage: 19 ml, once
    Start date: 2005-07-05
    End date: 2005-07-05

Other drugs received by patient: Viagra; Oxycodone Hydrochloride; Lisinopril; Mirapex; Sodium Citrate; Prednisone TAB; Norvasc; Zaroxolyn; Lasix; Compazine; Aspirin; Folic Acid; Spiriva; Calcitriol; Ativan; Cytoxan; Acetaminophen; Pentamidine Isethionate; Albuterol; Calcitonin Salmon; Phoslo; Lexapro; Pravachol; Labetalol HCL; MS Contin; Lopressor; Thiamine; Trazodone HCL; Protonix; Nephrovite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Renagel; Kayexalate; Darbepoetin Alfa; Wellbutrin; Normodyne; Coumadin; Flagyl; Heparin; Magnesium Oxide; Fosamax



Possible Prohance side effects in 51 year old female

Reported by a lawyer from United States on 2012-05-31

Patient: 51 year old female, weighing 64.1 kg (141.0 pounds)

Reactions: Peripheral Coldness, Pruritus, Skin Exfoliation, Pain, Erythema, Joint Stiffness, Skin Fissures, Dermatitis, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Skin Haemorrhage, Injury, Pain in Extremity, Motor Dysfunction, Skin Hypertrophy, DRY Skin, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Tightness, Sclerodactylia, Burning Sensation, Anxiety, Emotional Distress, Dysstasia, Activities of Daily Living Impaired, Insomnia, Mobility Decreased, Scar

Drug(s) suspected as cause:
Omniscan
    Indication: Venogram

Optimark
    Indication: Venogram

Magnevist
    Dosage: unk, once
    Indication: Venous Pressure Increased
    Start date: 2004-12-09
    End date: 2004-12-09

Magnevist
    Indication: Arteriovenous Fistula Operation
    Start date: 2006-11-28
    End date: 2006-11-28

Magnevist
    Indication: Dialysis Device Insertion

Multihance
    Indication: Fistulogram

Prohance
    Indication: Fistulogram

Magnevist
    Indication: Dialysis Efficacy Test
    Start date: 2006-09-26
    End date: 2006-09-26

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Fistulogram

Prohance
    Indication: Venogram

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2001-01-11
    End date: 2001-01-11

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Fistulogram

Multihance
    Indication: Venogram

Other drugs received by patient: Levothroid; Atenolol; Vicodin; Immune Globulin NOS; Tramadol HCL; Protonix; Pravachol; Sensipar; Sensipar; Imodium; Immune Globulin NOS; Benadryl; Fosrenol; Nitroglycerin; Corticosteroids; Calcium Carbonate; Renagel; Phoslo; Immune Globulin NOS; Immune Globulin NOS; Loperamide; Protonix; Nephro-Vite [vitamins Nos]; Allopurinol; Allopurinol; Cyclosporine; Acetaminophen; Benadryl; Coumadin; Epoetin NOS; Vitamin B12; Immune Globulin NOS; Acetaminophen; Ureacin; Omeprazole; Amiodarone HCL; Procardia XL; Prilosec; Nifedipine; Acetaminophen; Benadryl; Benadryl; Calcitriol; Metoclopramide; Levothroid; Coumadin; Coumadin; Calcium Carbonate; Plendil; Acetaminophen; Acetaminophen; Acetaminophen; Benadryl; PEG-3350 and Electrolytes; Cardizem; Prednisone TAB; Atenolol; Reglan; Renagel; Epogen; Pravastatin; Metoprolol Tartrate



Possible Prohance side effects in 57 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-25

Patient: 57 year old male, weighing 77.1 kg (169.6 pounds)

Reactions: Skin Wrinkling, Pruritus, Pain, Erythema, Joint Stiffness, Anhedonia, Fatigue, Joint Range of Motion Decreased, Skin Lesion, Oedema Peripheral, Musculoskeletal Stiffness, Injury, Peau D'orange, Pain in Extremity, Excoriation, Muscle Contracture, Muscular Weakness, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Hypoaesthesia, Skin Hypopigmentation, DRY Skin, Skin Induration, Skin Tightness, Skin Plaque, Anxiety, Emotional Distress, Arthralgia, Mobility Decreased, Skin Fibrosis, Scar

Drug(s) suspected as cause:
Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: unk, once
    Start date: 2005-10-18
    End date: 2005-10-18

Omniscan
    Dosage: unk, once
    Start date: 2005-10-21
    End date: 2005-10-21

Optimark
    Dosage: 19 ml, unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2005-04-20
    End date: 2005-04-20

Omniscan
    Dosage: unk, once
    Start date: 2005-10-01
    End date: 2005-10-01

Omniscan
    Dosage: unk, once
    Start date: 2005-09-06
    End date: 2005-09-06

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-09-08
    End date: 2005-09-08

Omniscan
    Dosage: unk, once
    Start date: 2005-09-28
    End date: 2005-09-29

Gadolinium IN Unspecified Drug
    Dosage: unk unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-03-17
    End date: 2006-03-17

Omniscan
    Dosage: unk unk, once
    Indication: Nuclear Magnetic Resonance Imaging Renal
    Start date: 2005-08-25
    End date: 2005-08-25

Omniscan
    Dosage: unk, once
    Indication: Venogram Renal
    Start date: 2005-09-01
    End date: 2005-09-01

Omniscan
    Dosage: unk, once
    Indication: Angiogram Peripheral
    Start date: 2005-08-30
    End date: 2005-08-30

Omniscan
    Dosage: unk, once
    Start date: 2005-11-03
    End date: 2005-11-03

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: unk, once
    Start date: 2005-10-03
    End date: 2005-10-03

Omniscan
    Dosage: unk

Optimark
    Dosage: 19 ml, once
    Start date: 2005-07-05
    End date: 2005-07-05

Other drugs received by patient: Cytoxan; Nephrovite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Pentamidine Isethionate; Oxycodone HCL; Wellbutrin; Coumadin; Lopressor; Aspirin; Folic Acid; Flagyl; Acetaminophen; Zaroxolyn; Normodyne; Compazine; Pravachol; Albuterol; Ativan; MS Contin; Fosamax; Thiamine; Calcitriol; Norvasc; Lasix; Darbepoetin Alfa; Heparin; Protonix; Calcitonin Salmon; Labetalol HCL; Renagel; Phoslo; Viagra; Sodium Citrate; Trazodone HCL; Mirapex; Spiriva; Prednisone TAB; Magnesium Oxide; Kayexalate; Lexapro; Lisinopril



Possible Prohance side effects in 50 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-18

Patient: 50 year old male, weighing 69.8 kg (153.6 pounds)

Reactions: Muscle Contractions Involuntary, Pain, Skin Hyperpigmentation, Joint Stiffness, Skin Discolouration, Joint Range of Motion Decreased, Oedema Peripheral, Musculoskeletal Stiffness, Fibrosis, General Physical Health Deterioration, Muscular Weakness, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Skin Induration, Arthralgia, Gait Disturbance, Skin Fibrosis, Mobility Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
Magnevist
    Dosage: 30 ml, once
    Start date: 2000-05-05
    End date: 2000-05-05

Unspecified Gadolinium Based Contrast Agent
    Dosage: unk
    Start date: 2006-07-14
    End date: 2006-07-14

Magnevist
    Dosage: 48 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2000-02-05
    End date: 2000-02-05

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Unspecified Gadolinium Based Contrast Agent
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2001-12-17
    End date: 2001-12-17

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 39 ml, once
    Start date: 2006-07-26
    End date: 2006-07-26

Unspecified Gadolinium Based Contrast Agent
    Indication: Angiogram
    Start date: 2000-10-01
    End date: 2000-10-15

Magnevist
    Dosage: 40 ml, once
    Start date: 2006-08-09
    End date: 2006-08-09

Other drugs received by patient: Prednisone; Imuran; Norvasc; Calcium Carbonate; Micardis; Oxycet; Darbepoetin Alfa; Minoxidil; Percocet; Renagel; Digoxin; Clonidine; Phoslo; Lanthanum Carbonate; Ferrlecit; Florinef; Lopressor; Plaquenil; Procardia; Zemplar; Coreg; Amiodarone HCL; Aspirin; Cortisone Acetate; Renaphro; Epogen; Vancomycin; Darbepoetin Alfa; Hectorol; Fosrenol



Possible Prohance side effects in 50 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-18

Patient: 50 year old male, weighing 69.8 kg (153.6 pounds)

Reactions: Muscle Contractions Involuntary, Pain, Skin Hyperpigmentation, Joint Stiffness, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Musculoskeletal Stiffness, Fibrosis, Muscular Weakness, General Physical Health Deterioration, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Skin Induration, Arthralgia, Gait Disturbance, Mobility Decreased, Skin Fibrosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Unspecified Gadolinium Based Contrast Agent
    Indication: Angiogram
    Start date: 2000-10-01
    End date: 2000-10-15

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Unspecified Gadolinium Based Contrast Agent
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2001-12-17
    End date: 2001-12-17

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 48 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2000-02-05
    End date: 2000-02-05

Magnevist
    Dosage: 39 ml, once
    Start date: 2006-07-26
    End date: 2006-07-26

Magnevist
    Dosage: 30 ml, once
    Start date: 2000-05-05
    End date: 2000-05-05

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 40 ml, once
    Start date: 2006-08-09
    End date: 2006-08-09

Unspecified Gadolinium Based Contrast Agent
    Dosage: unk
    Start date: 2006-07-14
    End date: 2006-07-14

Other drugs received by patient: Epogen; Renagel; Procardia; Aspirin; Lopressor; Minoxidil; Ferrlecit; Zemplar; Coreg; Norvasc; Calcium Carbonate; Lanthanum Carbonate; Renaphro; Imuran; Digoxin; Florinef; Cortisone Acetate; Plaquenil; Micardis; Amiodarone HCL; Darbepoetin Alfa; Prednisone; Hectorol; Vancomycin; Darbepoetin Alfa; Phoslo; Fosrenol; Clonidine; Percocet; Oxycet



Possible Prohance side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-11

Patient: female, weighing 108.8 kg (239.4 pounds)

Reactions: Erythema, Upper Extremity Mass, Joint Stiffness, Muscle Fatigue, Proteinuria, Oedema Peripheral, Renal Cortical Necrosis, Pain in Extremity, Skin Induration, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Stress, Emotional Distress, Rash Erythematous, Scar, Soft Tissue Disorder, Pain, Skin Hyperpigmentation, Myosclerosis, Skin Discolouration, Joint Range of Motion Decreased, Oedema, Musculoskeletal Stiffness, Injury, Renal Failure Acute, Musculoskeletal Pain, Rash Papular, Skin Disorder, Renal Failure Chronic, Burning Sensation, Anxiety, Dysstasia, Limb Discomfort, Arthralgia, Renal Tubular Necrosis

Drug(s) suspected as cause:
Magnevist
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2004-10-01

Magnevist
    Dosage: daily dose 20 ml
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2007-09-05
    End date: 2007-09-05

Optimark

Multihance

Magnevist
    Dosage: unk
    Start date: 2005-05-26

Omniscan

Magnevist
    Dosage: unk
    Start date: 2004-10-07

Omnipaque 140
    Dosage: 150 ml, unk
    Indication: Computerised Tomogram Abdomen
    Start date: 2004-09-30
    End date: 2004-09-30

Hypaque-M [meglumine Amidotrizoate]
    Dosage: unk
    Administration route: Oral
    Indication: Computerised Tomogram Abdomen
    Start date: 2004-10-06
    End date: 2004-10-06

Prohance

Magnevist
    Dosage: unk
    Start date: 2005-05-09

Magnevist
    Dosage: unk
    Start date: 2004-11-18

Magnevist
    Dosage: unk
    Start date: 2005-05-23

Other drugs received by patient: Cytoxan; Xanax; Sensipar; Ferrous Sulfate TAB; Contrast Media; Immune Globulin NOS; Gabapentin; Valcyte; Contrast Media; Prednisone; Lasix; Marijuana; Midodrine Hydrochloride; Lisinopril; Aspirin; Norvasc; Cyclobenzaprine; Calcium +vit D; Coumadin; Contrast Media; Lopressor; Epogen; Cellcept; Nephrovite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Iron; Gengraf; Renagel



Possible Prohance side effects in 31 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-10

Patient: 31 year old female, weighing 59.8 kg (131.6 pounds)

Reactions: Pruritus, Pain, Joint Contracture, Skin Burning Sensation, Muscle Spasticity, Joint Stiffness, Myalgia, Skin Discolouration, Joint Range of Motion Decreased, Oedema Peripheral, Musculoskeletal Stiffness, Skin Swelling, Pain in Extremity, Muscle Contracture, Muscular Weakness, Skin Induration, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, DRY Skin, Stress, Skin Tightness, Finger Deformity, Anxiety, Arthralgia, Exfoliative Rash, Gait Disturbance, Atrophy

Drug(s) suspected as cause:
Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Angiogram

Multihance
    Indication: Angiogram

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: unk
    Indication: Angiogram
    Start date: 2003-01-10
    End date: 2003-01-10

Prohance
    Indication: Angiogram

Optimark
    Indication: Nuclear Magnetic Resonance Imaging Brain

Magnevist
    Dosage: unk
    Indication: Angiogram
    Start date: 2007-01-18
    End date: 2007-01-18

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2003-09-22
    End date: 2003-09-22

Other drugs received by patient: Amlodipine Besylate; Accupril; Ibuprofen; Renagel; Cardura; Depakote; Amiodarone HCL; Elavil; Pravastatin; Labetalol HCL; Phenytoin; Aspirin; Metoprolol Tartrate; Morphine; Plendil; Lovenox; Methadone HCL; Lidocaine; Vitamin K TAB; Clonidine; Heparin; Lamictal; Folic Acid; Enoxaparin; Promethazine; Norvasc; Cardizem; Coumadin; Prednisone TAB; Diazepam; Dilantin; Vicodin; Xanax



Possible Prohance side effects in female

Reported by a consumer/non-health professional from United States on 2012-05-07

Patient: female

Reactions: Pain, Skin Hyperpigmentation, Skin Hypertrophy, DRY Skin, Nephrogenic Systemic Fibrosis, Skin Induration, Muscle Tightness, Joint Range of Motion Decreased, Oedema Peripheral, Ocular Icterus, Extremity Contracture, Scleral Disorder

Drug(s) suspected as cause:
Omniscan
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2004-07-20

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Angiogram

Magnevist

Prohance
    Indication: Angiogram

Other drugs received by patient: Labetalol HCL; Coumadin; Zocor



Possible Prohance side effects in 57 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-03

Patient: 57 year old male, weighing 77.1 kg (169.6 pounds)

Reactions: Skin Wrinkling, Pruritus, Pain, Erythema, Joint Stiffness, Anhedonia, Fatigue, Joint Range of Motion Decreased, Oedema Peripheral, Skin Lesion, Musculoskeletal Stiffness, Injury, Peau D'orange, Pain in Extremity, Muscular Weakness, Hypoaesthesia, DRY Skin, Skin Hypertrophy, Skin Hypopigmentation, Nephrogenic Systemic Fibrosis, Skin Plaque, Skin Tightness, Anxiety, Emotional Distress, Arthralgia, Mobility Decreased, Scar

Drug(s) suspected as cause:
Omniscan
    Dosage: unk, once
    Indication: Venogram Renal
    Start date: 2005-09-01
    End date: 2005-09-01

Omniscan
    Dosage: unk, once
    Start date: 2005-09-28
    End date: 2005-09-29

Omniscan
    Dosage: unk, once
    Start date: 2005-11-03
    End date: 2005-11-03

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: unk unk, once
    Indication: Renal Scan
    Start date: 2005-08-25
    End date: 2005-08-25

Optimark
    Dosage: 19 ml, once
    Start date: 2005-07-05
    End date: 2005-07-05

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-09-08
    End date: 2005-09-08

Omniscan
    Dosage: unk, once
    Start date: 2005-10-01
    End date: 2005-10-01

Omniscan
    Dosage: unk, once
    Start date: 2005-10-18
    End date: 2005-10-18

Optimark
    Dosage: 19 ml, unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2005-04-20
    End date: 2005-04-20

Omniscan
    Dosage: unk, once
    Indication: Angiogram Peripheral
    Start date: 2005-08-30
    End date: 2005-08-30

Omniscan
    Dosage: unk

Omniscan
    Dosage: unk, once
    Start date: 2005-10-03
    End date: 2005-10-03

Omniscan
    Dosage: unk, once
    Start date: 2005-10-21
    End date: 2005-10-21

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Dosage: unk unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-03-17
    End date: 2006-03-17

Omniscan
    Dosage: unk, once
    Start date: 2005-09-06
    End date: 2005-09-06

Other drugs received by patient: Pravachol; Sodium Citrate; Kayexalate; Oxycodone HCL; Aspirin; Prednisone; Calcitonin Salmon; Zaroxolyn; MS Contin; Lexapro; Lisinopril; Coumadin; Pentamidine; Compazine; Spiriva; Ativan; Norvasc; Lasix; Nephrovite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Renagel; Flagyl; Calcitriol; Labetalol HCL; Phoslo; Normodyne; Lopressor; Thiamine; Cytoxan; Wellbutrin; Viagra; Heparin; Trazodone HCL; Protonix; Darbepoetin Alfa; Fosamax; Folic Acid; Albuterol; Acetaminophen; Magnesium Oxide; Mirapex



Possible Prohance side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-03

Patient: female, weighing 108.8 kg (239.4 pounds)

Reactions: Soft Tissue Disorder, Pain, Skin Hyperpigmentation, Upper Extremity Mass, Erythema, Joint Stiffness, Myosclerosis, Muscle Fatigue, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Proteinuria, Oedema, Musculoskeletal Stiffness, Injury, Renal Failure Acute, Renal Cortical Necrosis, Pain in Extremity, Musculoskeletal Pain, Rash Papular, Skin Disorder, Skin Hypertrophy, Skin Induration, Nephrogenic Systemic Fibrosis, Stress, Renal Failure Chronic, Emotional Distress, Anxiety, Burning Sensation, Limb Discomfort, Dysstasia, Arthralgia, Rash Erythematous, Renal Tubular Necrosis, Scar

Drug(s) suspected as cause:
Magnevist
    Dosage: unk
    Start date: 2005-05-23

Magnevist
    Dosage: daily dose 20 ml
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2007-09-05
    End date: 2007-09-05

Magnevist
    Dosage: unk
    Start date: 2004-10-07

Omnipaque 140
    Dosage: 150 ml, unk
    Indication: Computerised Tomogram Abdomen
    Start date: 2004-09-30
    End date: 2004-09-30

Omniscan

Magnevist
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2004-10-01

Hypaque-M [meglumine Amidotrizoate]
    Dosage: unk
    Administration route: Oral
    Indication: Computerised Tomogram Abdomen
    Start date: 2004-10-06
    End date: 2004-10-06

Magnevist
    Dosage: unk
    Start date: 2005-05-09

Prohance

Magnevist
    Dosage: unk
    Start date: 2004-11-18

Optimark

Magnevist
    Dosage: unk
    Start date: 2005-05-26

Multihance

Other drugs received by patient: Immune Globulin NOS; Lopressor; Epogen; Midodrine Hydrochloride; Cytoxan; Iron; Gengraf; Xanax; Calcium +vit D; Nephrovite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Aspirin; Valcyte; Coumadin; Contrast Media; Renagel; Ferrous Sulfate TAB; Lisinopril; Norvasc; Prednisone; Marijuana; Cyclobenzaprine; Gabapentin; Lasix; Sensipar; Contrast Media; Contrast Media; Mycophenolate Mofetil (Cellcept)



Possible Prohance side effects in 34 year old male

Reported by a lawyer from United States on 2012-04-30

Patient: 34 year old male

Reactions: Pain, Joint Contracture, Skin Hyperpigmentation, Joint Range of Motion Decreased, Fibrosis, Depression, Muscular Weakness, Skin Induration, Nephrogenic Systemic Fibrosis, Hypoaesthesia, Skin Hypertrophy, Skin Tightness, Skin Plaque, Emotional Distress, Anxiety, Insomnia, Gait Disturbance

Drug(s) suspected as cause:
Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Prohance

Omniscan
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 1999-01-11
    End date: 1999-01-11

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Prohance
    Dosage: 17 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-08-15
    End date: 2006-08-15

Other drugs received by patient: Oxycodone HCL; Venlafaxine; Nephrox [aluminium Hydroxide]; Calcium Acetate; Lisinopril; Coreg; Metoprolol Tartrate; Sensipar; Nifedipine; Lactulose; Aspirin; Rena-Vite; Accupril; Coumadin; Omeprazole; Fosrenol; EPO; Alprazolam; Norvasc; Chromagen [ascorbic Acid,cyanocobalamin,ferrous Fumarate,folic ACI; Nephrovite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]



Possible Prohance side effects in 51 year old female

Reported by a consumer/non-health professional from United States on 2012-04-12

Patient: 51 year old female, weighing 94.0 kg (206.8 pounds)

Reactions: Pain, Joint Contracture, Muscle Tightness, Joint Stiffness, Anhedonia, Oedema Peripheral, Oedema, Musculoskeletal Stiffness, Depression, Dyspnoea, Pain in Extremity, Muscle Contracture, Muscular Weakness, Skin Disorder, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Skin Induration, Deformity, Skin Tightness, Anxiety, Joint Swelling, Arthralgia, Mobility Decreased, Skin Fibrosis, Scar

Drug(s) suspected as cause:
Magnevist
    Indication: Hypoaesthesia

Omniscan
    Indication: Imaging Procedure

Multihance
    Indication: Imaging Procedure

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2002-04-03
    End date: 2002-04-03

Prohance
    Indication: Imaging Procedure

Optimark
    Indication: Imaging Procedure

Other drugs received by patient: Epogen; Iron [iron]; Antibiotics; Warfarin Sodium; Calcium Carbonate; Procrit; Coumadin; Evista; Renagel; Renal [vitamins Nos]; Nexium; Lipitor; Sensipar; Aspirin



Possible Prohance side effects in 51 year old female

Reported by a lawyer from United States on 2012-04-12

Patient: 51 year old female, weighing 64.1 kg (141.0 pounds)

Reactions: Peripheral Coldness, Pruritus, Skin Exfoliation, Pain, Erythema, Joint Stiffness, Skin Fissures, Joint Range of Motion Decreased, Skin Discolouration, Dermatitis, Oedema Peripheral, Skin Haemorrhage, Injury, Pain in Extremity, Motor Dysfunction, Skin Induration, Nephrogenic Systemic Fibrosis, DRY Skin, Skin Hypertrophy, Sclerodactylia, Skin Tightness, Anxiety, Emotional Distress, Burning Sensation, Dysstasia, Activities of Daily Living Impaired, Insomnia, Mobility Decreased, Scar

Drug(s) suspected as cause:
Optimark
    Indication: Fistulogram

Magnevist
    Indication: Arteriovenous Fistula Operation
    Start date: 2006-11-28
    End date: 2006-11-28

Omniscan
    Indication: Fistulogram

Optimark
    Indication: Venogram

Magnevist
    Dosage: unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2001-01-11
    End date: 2001-01-11

Prohance
    Indication: Fistulogram

Magnevist
    Dosage: unk, once
    Indication: Venous Pressure Increased
    Start date: 2004-12-09
    End date: 2004-12-09

Prohance
    Indication: Venogram

Multihance
    Indication: Venogram

Omniscan
    Indication: Venogram

Magnevist
    Indication: Dialysis Efficacy Test
    Start date: 2006-09-26
    End date: 2006-09-26

Magnevist
    Indication: Dialysis

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Fistulogram

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Atenolol; Allopurinol; Acetaminophen; Calcitriol; Nitroglycerin; Omeprazole; Atenolol; Acetaminophen; Acetaminophen; Loperamide; Tramadol HCL; Coumadin; Renagel; Nifedipine; Vitamin B12; Immune Globulin NOS; Acetaminophen; Fosrenol; Cardizem; Corticosteroids; Protonix; Renagel; Nephro-Vite [vitamins Nos]; Allopurinol; Acetaminophen; Benadryl; Benadryl; Calcium Carbonate; Reglan; Amiodarone HCL; Vicodin; Phoslo; Plendil; Ureacin; Prednisone TAB; Levothroid; Calcium Carbonate; Epogen; Procardia XL; Pravachol; Prilosec; Sensipar; Cyclosporine; Imodium; Benadryl; Benadryl; Pravastatin; Levothroid; Coumadin; Immune Globulin NOS; Acetaminophen; Benadryl; Coumadin; Protonix; Epoetin NOS; Sensipar; Immune Globulin NOS; Immune Globulin NOS; Immune Globulin NOS; Metoclopramide; PEG-3350 and Electrolytes; Metoprolol Tartrate



Possible Prohance side effects in 31 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-11

Patient: 31 year old female, weighing 59.8 kg (131.6 pounds)

Reactions: Pruritus, Pain, Joint Contracture, Skin Burning Sensation, Joint Stiffness, Myalgia, Skin Discolouration, Joint Range of Motion Decreased, Oedema Peripheral, Musculoskeletal Stiffness, Skin Swelling, Pain in Extremity, Muscular Weakness, DRY Skin, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Skin Induration, Stress, Skin Tightness, Finger Deformity, Anxiety, Arthralgia, Exfoliative Rash, Gait Disturbance, Atrophy

Drug(s) suspected as cause:
Omniscan
    Dosage: unk
    Indication: Angiogram
    Start date: 2003-01-10
    End date: 2003-01-10

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2003-09-22
    End date: 2003-09-22

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Prohance
    Indication: Angiogram

Optimark
    Indication: Angiogram

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Nuclear Magnetic Resonance Imaging Brain

Multihance
    Indication: Angiogram

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: unk
    Indication: Angiogram
    Start date: 2007-01-18
    End date: 2007-01-18

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Dilantin; Amlodipine; Prednisone; Plendil; Aspirin; Cardizem; Lamictal; Vitamin K TAB; Pravastatin; Metoprolol Tartrate; Labetalol HCL; Methadone HCL; Clonidine; Promethazine; Vicodin; Ibuprofen; Renagel; Cardura; Coumadin; Elavil; Enoxaparin; Lidocaine; Amiodarone HCL; Norvasc; Diazepam; Lovenox; Accupril; Phenytoin; Morphine; Heparin; Depakote



Possible Prohance side effects in 54 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-11

Patient: 54 year old male, weighing 93.9 kg (206.5 pounds)

Reactions: Hyperkeratosis, Skin Exfoliation, Pain, Joint Contracture, Scleroderma, Skin Hyperpigmentation, Erythema, Joint Range of Motion Decreased, Oedema Peripheral, Skin Swelling, Papule, General Physical Health Deterioration, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, DRY Skin, Deformity, Skin Plaque, Skin Tightness, Sclerodactylia, Macule

Drug(s) suspected as cause:
Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2006-01-14
    End date: 2006-01-14

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 1999-10-28
    End date: 1999-10-28

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-08-13
    End date: 2008-08-13

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-11-18
    End date: 2008-11-18

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 1999-09-20
    End date: 1999-09-20

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2007-03-21
    End date: 2007-03-21

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Fistulogram
    Start date: 1999-10-08
    End date: 1999-10-08

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 1999-10-13
    End date: 1999-10-13

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2006-02-04
    End date: 2006-02-04

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 1999-09-27
    End date: 1999-09-27

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-03-19
    End date: 2008-03-19

Other drugs received by patient: Rena-Vite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Renvela; Phoslo; Calcium Acetate; Renal [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Acetaminophen and Hydrocodone Bitartrate; Iron; Sensipar; Aspirin



Possible Prohance side effects in 61 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-11

Patient: 61 year old male, weighing 160.9 kg (354.0 pounds)

Reactions: Thrombosis, Visual Acuity Reduced, Skin Hyperpigmentation, Hyperhidrosis, Dermatitis, Oedema Peripheral, Back Pain, Pain in Extremity, General Physical Health Deterioration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Skin Induration, Hypoaesthesia, Deformity, Tremor, Anxiety, Arthralgia, Scar

Drug(s) suspected as cause:
Magnevist
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2001-03-02
    End date: 2001-03-02

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging Brain

Magnevist
    Dosage: unk unk, once
    Indication: Renal Mass
    Start date: 2004-03-29
    End date: 2004-03-29

Omniscan
    Indication: Imaging Procedure

Optimark
    Indication: Back Pain

Prohance
    Indication: Imaging Procedure

Optimark
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-02-22
    End date: 2006-02-22

Multihance
    Indication: Imaging Procedure

Other drugs received by patient: Warfarin Sodium; Bextra; Celebrex; Prilosec; Dynacirc; Testosterone; Vitamin B12 NOS; Ibuprofen; Flomax; Water Purified; Lortab; Viagra; NTP; Hydrochlorothiazide; Dovonex; Avapro; Prevacid; Vitamin B6; Aspirin



Possible Prohance side effects in 57 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-09

Patient: 57 year old female, weighing 66.0 kg (145.2 pounds)

Reactions: Pruritus, Skin Hyperpigmentation, Skin Discolouration, Skin Lesion, Skin Atrophy, Muscle Spasms, Peau D'orange, Pain in Extremity, Musculoskeletal Pain, Skin Disorder, General Physical Health Deterioration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Skin Hypopigmentation, Deformity, Skin Tightness, Arthralgia, Lichenification, Xerosis, Scar

Drug(s) suspected as cause:
Omniscan
    Indication: Imaging Procedure

Optimark
    Indication: Imaging Procedure

Magnevist
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2004-07-09
    End date: 2004-07-09

Magnevist

Multihance
    Indication: Imaging Procedure

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2002-05-20
    End date: 2002-05-20

Prohance
    Dosage: 15 ml, unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2003-01-14
    End date: 2003-01-14

Prohance
    Dosage: unk
    Start date: 2006-10-20
    End date: 2006-10-20

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2001-04-20
    End date: 2001-04-20

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2006-05-24
    End date: 2006-05-24

Other drugs received by patient: Ambien; Antiglaucoma Preparations and Miotics; Phenazopyridine HCL TAB; Tigan; MS Contin; Vibramycin; Lorcet-HD; MS Contin; Percocet; Xalatan; Antiglaucoma Preparations and Miotics; Antivert; Celexa; Augmentin '125'; Protonix; Ciprofloxacin HCL; Bactrim DS; Symbicort; Effexor; Mucinex; Depo; Orapred; Morphine Sulfate; Pyridiate; Singulair; Hycodan; Oxycontin; Combivent



Possible Prohance side effects in 54 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-27

Patient: 54 year old male, weighing 93.9 kg (206.5 pounds)

Reactions: Gastrointestinal Haemorrhage, Hyperkeratosis, Morphoea, Pain, Erythema, Gastritis, Hand Deformity, Skin Discolouration, Oedema Peripheral, Lipoma, Emotional Disorder, Skin Swelling, Tendonitis, Haemorrhoids, Rash Papular, General Physical Health Deterioration, Patellofemoral Pain Syndrome, Nephrogenic Systemic Fibrosis, DRY Skin, Skin Induration, Skin Hypertrophy, Renal Failure Chronic, Deformity, Skin Tightness, Haemodialysis, Sclerodactylia, Osteoarthritis, Mental Disorder

Drug(s) suspected as cause:
Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 1999-09-20
    End date: 1999-09-20

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2007-03-21
    End date: 2007-03-21

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2006-02-04
    End date: 2006-02-04

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-11-18
    End date: 2008-11-18

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2006-01-14
    End date: 2006-01-14

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 1999-09-27
    End date: 1999-09-27

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Fistulogram
    Start date: 1999-10-08
    End date: 1999-10-08

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 1999-10-13
    End date: 1999-10-13

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-08-13
    End date: 2008-08-13

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 1999-10-28
    End date: 1999-10-28

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-03-19
    End date: 2008-03-19

Other drugs received by patient: Calcium Acetate; Acetaminophen and Hydrocodone Bitartrate; Aspirin; Phoslo; Sensipar; Renal [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Rena-Vite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Renvela; Iron



Possible Prohance side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-19

Patient: male, weighing 77.0 kg (169.4 pounds)

Reactions: Pain, Myosclerosis, Joint Stiffness, Neuropathy Peripheral, Joint Range of Motion Decreased, Oedema Peripheral, Oedema, Fibrosis, Transient Ischaemic Attack, Pain in Extremity, Rash Papular, General Physical Health Deterioration, Skin Induration, Rash, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Deformity, Onychomadesis, Skin Tightness, Skin Plaque, Arthralgia, Joint Swelling, Alopecia, Mobility Decreased, Scar

Drug(s) suspected as cause:
Optimark
    Indication: Imaging Procedure

Magnevist
    Indication: Imaging Procedure

Omniscan
    Dosage: unk
    Indication: Imaging Procedure
    Start date: 2004-07-01
    End date: 2004-07-01

Multihance
    Indication: Imaging Procedure

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2002-04-10
    End date: 2002-04-10

Omniscan
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2004-07-18
    End date: 2004-07-18

Prohance
    Indication: Imaging Procedure

Omniscan

Other drugs received by patient: Neutra-Phos; Monopril; Epogen; Felodipine; Gengraf; Rapamune; Plavix; Iron; Mycophenolate Mofetil (Cellcept); Nephrovite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Vicodin; Plendil; Bactrim; Metoprolol Succinate; Zoloft; Neoral; Renagel; Enalapril; Prednisone; Calcium Carbonate; Nexium; Aspirin; Altace



Possible Prohance side effects in 53 year old female

Reported by a pharmacist from United States on 2012-03-19

Patient: 53 year old female, weighing 114.7 kg (252.4 pounds)

Reactions: Pruritus, Pain, Erythema, Anhedonia, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Injury, Pain in Extremity, Localised Oedema, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Skin Tightness, Emotional Distress, Anxiety, Arthralgia, Activities of Daily Living Impaired, Skin Mass, Mobility Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Xopenex; Vasotec; Demedex; Enalapril; Sensipar; Astelin; Phoslo; Vasopressin; Humulin N; Zelnorm; Ativan; Wellbutrin XL; Aspirin; Santyl; Norco; Keppra; Avandia; Allopurinol; Epogen; Aspirin; Torsemide; Neurontin; Hydrocodone Bitartrate and Acetaminophen; Synthroid; Regular Insulin; Renagel; NPH Insulin; Atrovent; Zyloprim; Mirapex; Glucotrol; Ibuprofen



Possible Prohance side effects in 48 year old male

Reported by a consumer/non-health professional from United States on 2012-03-06

Patient: 48 year old male, weighing 98.0 kg (215.5 pounds)

Reactions: Pruritus, Joint Contracture, Pain, Scleroderma, Erythema, Joint Range of Motion Decreased, Oedema Peripheral, Musculoskeletal Stiffness, Nodule, Fibrosis, Pain in Extremity, Muscle Contracture, Skin Induration, Nephrogenic Systemic Fibrosis, Hypoaesthesia, Skin Hypertrophy, Skin Tightness, Paraesthesia, Emotional Distress, Grip Strength Decreased, Gait Disturbance, Asthenia, Skin Fibrosis

Drug(s) suspected as cause:
Magnevist
    Dosage: unk
    Indication: Peripheral Arterial Occlusive Disease
    Start date: 2002-07-10
    End date: 2002-07-10

Magnevist
    Dosage: unk
    Start date: 2006-07-25
    End date: 2006-07-25

Magnevist
    Dosage: unk
    Start date: 2002-07-03
    End date: 2002-07-03

Magnevist
    Dosage: unk
    Start date: 2003-03-11
    End date: 2003-03-11

Optimark
    Indication: Product Used FOR Unknown Indication

Magnevist
    Dosage: unk
    Start date: 2005-05-17
    End date: 2005-05-17

Prohance
    Indication: Product Used FOR Unknown Indication

Magnevist
    Dosage: unk
    Start date: 2001-04-27
    End date: 2001-04-27

Multihance
    Indication: Product Used FOR Unknown Indication

Magnevist
    Dosage: unk
    Indication: Angiogram
    Start date: 2001-04-19
    End date: 2001-04-19

Omniscan
    Indication: Product Used FOR Unknown Indication

Other drugs received by patient: Cleocin Hydrochloride; Pravastatin; Benoxyl [benzoyl Peroxide]; Colace; Furosemide; Zemplar; Norvasc; Nitroglycerin; Pravachol; Amitriptyline HCL; Coumadin; Colchicine; Valium; Zocor; Prednisone TAB; Neurontin; Sevelamer; Clonidine HCL; Epogen; Quinapril; Lyrica



Possible Prohance side effects in 54 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-05

Patient: 54 year old male

Reactions: Pain, General Physical Health Deterioration, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Deformity, Skin Tightness, Skin Discolouration, Skin Swelling

Drug(s) suspected as cause:
Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging



Possible Prohance side effects in 47 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-02

Patient: 47 year old female, weighing 58.0 kg (127.7 pounds)

Reactions: Pruritus, Pain, Erythema, Trigger Finger, Joint Stiffness, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Musculoskeletal Stiffness, Muscle Spasms, Peau D'orange, Pain in Extremity, Muscle Contracture, Skin Disorder, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Hypoaesthesia, Skin Induration, Skin Tightness, Paraesthesia, Burning Sensation, Activities of Daily Living Impaired, Grip Strength Decreased, Gait Disturbance, Skin Fibrosis, Mobility Decreased

Drug(s) suspected as cause:
Magnevist
    Dosage: 14 ml, once
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2001-01-03
    End date: 2001-01-03

Magnevist
    Dosage: 12 ml, once
    Start date: 2002-03-26

Magnevist
    Dosage: 20 ml, once
    Start date: 2004-01-02
    End date: 2004-01-02

Gadolinium IN Unspecified Drug

Omniscan
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 1997-07-18
    End date: 1997-07-18

Multihance
    Dosage: 8 ml, once
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2008-01-03
    End date: 2008-01-03

Magnevist
    Dosage: 15 ml, once
    Start date: 2003-08-13
    End date: 2003-08-13

Omniscan
    Dosage: 10 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 1998-06-01
    End date: 1998-06-01

Multihance
    Dosage: daily dose 8 ml
    Start date: 2009-01-03
    End date: 2009-01-03

Magnevist
    Dosage: 20 ml, once
    Start date: 2005-06-29
    End date: 2005-06-29

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 1999-06-15
    End date: 1999-06-15

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 1999-09-15
    End date: 1999-09-15

Omniscan
    Dosage: unk
    Start date: 2001-11-08
    End date: 2001-11-08

Magnevist
    Dosage: 12 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2002-03-18
    End date: 2002-03-18

Magnevist
    Dosage: 20 ml, once
    Start date: 2002-12-30
    End date: 2002-12-30

Gadolinium IN Unspecified Drug
    Dosage: daily dose 5 ml
    Indication: Haemorrhage Intracranial

Omniscan
    Dosage: unk
    Start date: 2001-03-05
    End date: 2001-03-05

Magnevist
    Dosage: 17 ml, once
    Start date: 2006-12-11

Gadolinium IN Unspecified Drug
    Indication: Angiogram Cerebral

Omniscan
    Dosage: unk
    Start date: 2001-10-30
    End date: 2001-10-30

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: ^14 ml and 16 ml^
    Start date: 2005-12-15
    End date: 2005-12-15

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 11 ml, once
    Start date: 2002-09-10
    End date: 2002-09-10

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2000-03-23
    End date: 2000-03-23

Omniscan
    Dosage: unk
    Start date: 2000-03-23
    End date: 2000-03-23

Multihance
    Dosage: unk
    Start date: 2008-03-31
    End date: 2008-03-31

Magnevist
    Dosage: 14 ml, once
    Start date: 2000-08-30
    End date: 2000-08-30

Magnevist
    Dosage: 14 ml, once
    Start date: 2000-12-21
    End date: 2000-12-21

Magnevist
    Dosage: 20 ml, once
    Start date: 2004-12-03
    End date: 2004-12-03

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2002-04-23
    End date: 2002-04-23

Multihance
    Dosage: 7 ml, unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2008-01-11
    End date: 2008-01-11

Multihance
    Dosage: daily dose 17 ml
    Start date: 2008-03-25
    End date: 2008-03-25

Other drugs received by patient: Procrit; Calcitriol; Dilantin; Epogen; Procrit; Gabapentin; Warfarin Sodium; Other Immunosuppressive Agents; Prednisone TAB; Chlorthalidone; Paxil; Lopressor; Prilosec; Mycelex; Amphojel [aluminium Oxide]; Ranitidine; Zofran; Oxycontin; Famvir; Lasix; Phoslo; Oxycodone HCL; Oxycodone HCL and Acetaminophen; Renagel; Metoprolol Succinate; Claritin; Thalomid; Imitrex; Atenolol; Thalidomide; Renagel; Nephrocaps; Neurontin; Fosamax; Klonopin; Neurontin; Amitriptyline HCL; Acyclovir; Ranitidine; Renaphro; Rena-Vite; Metoprolol Succinate; Zetia; Synthroid; Zoloft; Coumadin; Senokot; Rocaltrol; Prednisone TAB; Nephrovite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Furosemide; Tizanidine HCL; Lipitor; Sodium Bicarbonate; Acetaminophen and Oxycodone HCL; Mycophenolate Mofetil (Cellcept); Immune Globulin NOS; Nephrocaps [folic Acid,vitamins Nos]; Lasix; Ativan; Marinol; Prograf; Lipitor



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014